Delcath Systems (DCTH) 10-K 29 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 28, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	DELCATH SYSTEMS, INC.
Entity Central Index Key	872,912
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 5,973,172
Entity Common Stock, Shares Outstanding		113,457,971
Document Fiscal Year Focus	2,016
Trading Symbol	DCTH
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		Dec. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents		$ 4,409	$ 12,607
Restricted cash		27,287	0
Accounts receivables, net		403	277
Inventories		660	757
Prepaid expenses and other current assets		698	960
Deferred financing costs		699	0
Total current assets		34,156	14,601
Property, plant and equipment, net		1,083	1,132
Total assets		35,239	15,733
Current liabilities
Accounts payable		594	284
Accrued expenses		3,407	2,243
Convertible notes payable, net of debt discount		13,343	0
Warrant liability		18,751	3,785
Total current liabilities		36,095	6,312
Deferred revenue		30	0
Other non-current liabilities		604	820
Total liabilities		36,729	7,132
Commitments and contingencies (Note 12)
Stockholders' Equity (Deficit)
Preferred stock, $.01 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively		0	0
Common stock, $.01 par value; 500,000,000 shares authorized; 4,131,527 and 4,112,417 shares issued and 1,396,348 and 1,360,239 shares outstanding at December 31, 2016 and December 31, 2015, respectively	[1]	41	14
Additional paid-in capital		277,749	269,863
Accumulated deficit		(279,188)	(261,217)
Treasury stock, at cost; 110 shares at December 31, 2016 and December 31, 2015, respectively	[1]	(51)	(51)
Accumulated other comprehensive loss		(41)	(8)
Total stockholders' equity (deficit)		(1,490)	8,601
Total liabilities and stockholders' equity (deficit)		$ 35,239	$ 15,733
[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2016$ / sharesshares	Dec. 31, 2015$ / sharesshares
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share) | $ / shares	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	4,131,527	1,396,344
Common stock, shares outstanding (in shares)	4,112,417	1,360,239
Treasury stock, at cost (in shares)	110	110

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Product revenue		$ 1,992	$ 1,747
Cost of goods sold		(550)	(462)
Gross profit		1,442	1,285
Operating expenses:
Selling, general and administrative expenses		9,434	10,009
Research and development costs		8,448	6,486
Total operating expenses		17,882	16,495
Operating loss		(16,440)	(15,210)
Derivative instrument income		12,780	564
Interest income		17	9
Other expense and interest expense		(14,328)	(67)
Net loss		(17,971)	(14,704)
Other comprehensive loss:
Foreign currency translation adjustments		(33)	(28)
Comprehensive Loss		$ (18,004)	$ (14,732)
Common share data:
Basic and diluted loss per share	[1]	$ (10.59)	$ (14.56)
Weighted average number of basic and diluted shares outstanding	[1]	1,696,237	1,010,105
[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016

Consolidated Statements of Ope5

Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)	Jul. 21, 2016
Income Statement [Abstract]
Reverse stock split ratio	0.0625

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands		Total	Common Stock Issued [Member]		In Treasury [Member]		Additional Paid-in Capital [Member]	[1]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (loss) income [Member]
Balance at Dec. 31, 2014		$ 18,145	$ 6	[1]	$ (51)	[1]	$ 264,683		$ (246,513)	$ 20
Balance (in shares) at Dec. 31, 2014	[1]		608,775		(110)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options		349	$ 0	[1]	$ 0	[1]	349		0	0
Compensation expense for issuance of restricted stock		308	$ 0	[1]	$ 0	[1]	308		0	0
Compensation expense for issuance of restricted stock (in shares)	[1]		35,991		0
Sale of common stock, net of expenses		8,479	$ 8	[1]	$ 0	[1]	8,471		0	0
Sale of common stock, net of expenses (in shares)	[1]		738,125		0
Exercise of warrants		176	$ 0	[1]	$ 0	[1]	176		0	0
Exercise of warrants (in shares)	[1]		13,457		0
Fair value of warrants issued classified as liability		(4,247)	$ 0	[1]	$ 0	[1]	(4,247)		0	0
Fair value of warrants exercised		123	0	[1]	0	[1]	123		0	0
Net loss		(14,704)	0	[1]	0	[1]	0		(14,704)	0
Foreign currency translation		(28)	0	[1]	0	[1]	0		0	(28)
Balance at Dec. 31, 2015		8,601	$ 14	[1]	$ (51)	[1]	269,863		(261,217)	(8)
Balance (in shares) at Dec. 31, 2015	[1]		1,396,348		(110)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options		161	$ 0	[1]	$ 0	[1]	161		0	0
Compensation expense for issuance of restricted stock		266	$ 0	[1]	$ 0	[1]	266		0	0
Compensation expense for issuance of restricted stock (in shares)	[1]		2,180		0
Sale of common stock, net of expenses		1,011	$ 4	[1]	$ 0	[1]	1,007		0	0
Sale of common stock, net of expenses (in shares)	[1]		428,067		0
Issuance of common stock for payments made in shares on convertible notes payable		649	$ 18	[1]	$ 0	[1]	631		0	0
Issuance of common stock for payments made in shares on convertible notes payable (in shares)	[1]		1,805,299		0
Fair value of Beneficial conversion feature of convertible note		4,435	$ 0	[1]	$ 0	[1]	4,435		0	0
Exercise of warrants		1,372	$ 5	[1]	$ 0	[1]	1,367		0	0
Exercise of warrants (in shares)	[1]		499,633		0
Fair value of warrants issued classified as liability		(707)	$ 0	[1]	$ 0	[1]	(707)		0	0
Fair value of warrants exercised		726	0	[1]	0	[1]	726		0	0
Net loss		(17,971)	0	[1]	0	[1]	0		(17,971)	0
Foreign currency translation		(33)	0	[1]	0	[1]	0		0	(33)
Balance at Dec. 31, 2016		$ (1,490)	$ 41	[1]	$ (51)	[1]	$ 277,749		$ (279,188)	$ (41)
Balance (in shares) at Dec. 31, 2016	[1]		4,131,527		(110)
[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016

Consolidated Statements of Sto7

Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)	Jul. 21, 2016$ / shares	Dec. 31, 2016$ / shares	Dec. 31, 2015$ / shares
Statement Of Stockholders Equity [Abstract]
Common stock issued, par value	$ 0.01	$ 0.01	$ 0.01
Reverse stock split ratio	0.0625

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (17,971)	$ (14,704)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	161	349
Restricted stock compensation expense	266	308
Depreciation expense	305	617
Loss on disposal of equipment	1	15
Warrant liability fair value adjustment	(12,780)	(564)
Non-cash interest income	(1)	(1)
Debt discount and deferred finance costs amortization	14,268	0
Changes in assets and liabilities:
Decrease in prepaid expenses and other assets	260	9
Increase in accounts receivable	(138)	(52)
(Increase) decrease in inventories	95	(420)
Increase (decrease) in accounts payable and accrued expenses	1,507	(1,757)
Increase in deferred revenue	30	0
Decrease in other non-current liabilities	(216)	(220)
Net cash used in operating activities	(14,213)	(16,420)
Cash flows from investing activities:
Purchase of property, plant and equipment	(258)	(170)
Increase in restricted cash	(1,087)	0
Proceeds from sales of property, plant and equipment	0	180
Net cash provided by (used in) investing activities	(1,345)	10
Cash flows from financing activities:
Increase in restricted cash	(26,200)	0
Net proceeds from convertible debt financing	31,226	0
Net proceeds from sale of stock and exercise of warrants	2,383	8,655
Net cash provided by financing activities	7,409	8,655
Foreign currency effects on cash and cash equivalents	(49)	(107)
Net decrease in cash and cash equivalents	(8,198)	(7,862)
Cash and cash equivalents:
Beginning of period	12,607	20,469
End of period	4,409	12,607
Supplemental non-cash activities:
Conversion of convertible notes	649	0
Fair value of warrants issued	28,472	4,247
Fair value of warrants exercised	$ 726	$ 123

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	(1) Description of Business Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) —is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, our system is in commercial development under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT®), where it has been used at major medical centers to treat a wide range of cancers of the liver. Our primary research focus is on ocular melanoma liver metastases (mOM), intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC or primary liver), and certain other cancers that are metastatic to the liver. We believe the disease states we are investigating represent a multi-billion dollar global market opportunity and a clear unmet medical need. Liquidity The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and has accumulated deficit of $279.2 million at December 31, 2016. As shown in the accompanying financial statements during the year ended December 31, 2016, the Company incurred net losses of $18.0 million and used $14.2 million of cash for its operating activities. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time. The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital and/or enter into strategic alliances when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or any commercialization efforts. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. If we are not able to continue as a going concern, it is likely that holders of our common stock will lose all of their investment. The accompanying consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. On June 13, 2016 we issued an aggregate $35 million principal amount of senior secured convertible notes (the “Notes”). As a result, The Notes are payable in fourteen equal installments beginning in January 2017. Although the Notes are payable through the issuance of shares of our common stock to the noteholders, our ability to issue stock, instead of paying cash, to satisfy our payment obligations under the Notes, is limited and subject to various conditions (including trading volume and stock price conditions for these Notes) that we may not be able to meet. If we cannot meet these conditions, we could be required to repay some or all of the amounts due under the Notes in cash, and we may not have the funds available to make one or more of such payments when due.

Basis of Consolidated Financial

Basis of Consolidated Financial Statement Presentation	12 Months Ended
	Dec. 31, 2016
Basis Of Condensed Consolidated Financial Statement Presentation [Abstract]
Basis of Consolidated Financial Statement Presentation	(2) Basis of Consolidated Financial Statement Presentation The accounting and financial reporting policies of the Company conform to generally accepted accounting principles in the United States of America (GAAP). The preparation of consolidated financial statements in conformity with GAAP requires management to make assumptions and estimates that impact the amounts reported in the Company’s consolidated financial statements. The consolidated financial statements include the accounts of all entities controlled by Delcath. All significant inter-company accounts and transactions are eliminated.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(3) Summary of Significant Accounting Policies Use of Estimates The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s consolidated balance sheets and the amount of revenues and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, impairment of long-lived assets, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates. Cash Equivalents and Concentrations of Credit Risk The Company considers investments with original maturities of three months or less at date of acquisition to be cash equivalents. The Company has deposits that exceed amounts insured by the Federal Deposit Insurance Corporation (FDIC), however, the Company does not consider this a significant concentration of credit risk based on the strength of the financial institution. Restricted Cash Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on the accompanying consolidated balance sheets. On June 13, 2016, the Company issued $35.0 million in senior secured convertible notes and received $32.2 million in cash proceeds. Under the terms of the notes, at closing, an initial tranche of $3.0 million was available for immediate use by the Company for general corporate purposes. The remaining cash proceeds of $29.2 million were available in a tranche of $3.0 million on December 29, 2016 (“First Release Date”) and the remainder of $26.2 million will be available in four equal tranches to be released quarterly, beginning in February 2017 (“Subsequent Release Dates”), pursuant to an account control agreement whereby the restrictions on the proceeds are terminated when the Company meets certain equity conditions. The terms of the Notes are discussed in more detail in Note 9 contained in this Annual Report on Form 10-K. The cash is deposited in an account that is not FDIC insured. Accounts Receivable Accounts receivable, principally trade, are generally due within 30 days and are stated at amounts due from customers. Collections and payments from customers are monitored and a provision for estimated credit losses may be created based upon historical experience and specific customer collection issues that may be identified. Inventories Inventories are valued at the lower of cost or market value using the first-in, first-out method. The reported net value of inventory includes finished saleable products, work-in-process, and raw materials that will be sold or used in future periods. The Company reserves for expired, obsolete, and slow-moving inventory. Prior to obtaining authorization to affix the CE Mark to its Generation Two CHEMOSAT System in April 2012, the Company expensed all of its inventory costs as research and development. Inventory as of December 31, 2016 includes finished goods and components that have been purchased since April 2012. Therefore, to the extent that materials expensed prior to April 2012 are used in manufacturing finished goods for sale, the Company’s cost of goods sold will be impacted accordingly. Property, Plant and Equipment Property, plant and equipment are recorded at cost, less accumulated depreciation. The Company provides for depreciation on a straight line basis over the estimated useful lives of the assets which range from three to seven years. Leasehold improvements will be amortized over the shorter of the lease term or the estimated useful life of the related assets when they are placed into service. Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of the hedging relationship designation. Accounting for changes in the fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2016 and 2015, the Company did not have any derivative instruments that were designated as hedges. Fair Value Measurements The Company adheres to ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 applies to reported balances that are required or permitted to be measured at fair value under existing accounting pronouncements; accordingly, the standard does not require any new fair value measurements of reported balances. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). • Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. • Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. • Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. Revenue Recognition Revenue from product sales is generally recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred; product price is fixed or determinable; and collection of the resulting receivable is reasonably assured. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. Deferred Revenue Deferred revenue on the accompanying consolidated balance sheets includes payment received for product sales to a distributor. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied. Selling, General and Administrative Selling, general and administrative costs include personnel costs and related expenses for the Company’s sales, marketing, general management and administrative staff, recruitment, costs related to the Company’s commercialization efforts in Europe, professional service fees, professional license fees, business development and certain general legal activities. All such costs are charged to expense when incurred. Research and Development Research and development costs include the costs of materials used for clinical trials and R&D, personnel costs associated with device and pharmaceutical R&D, clinical affairs, medical affairs, medical science liaisons, and regulatory affairs, costs of outside services and applicable indirect costs incurred in the development of the Company’s proprietary drug delivery system. All such costs are charged to expense when incurred. Stock Based Compensation The Company accounts for its share-based compensation in accordance with the provisions of ASC 718, which establishes accounting for equity instruments exchanged for employee services and ASC 505-50, which establishes accounting for equity-based payments to non-employees. Under the provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders’ requisite service period (generally the vesting period of the equity grant). The Company is required to record compensation cost for all share-based payments granted to employees based upon the grant date fair value, estimated in accordance with the provisions of ASC 718. Under the provisions of ASC 505-50, measurement of compensation cost related to common shares issued to non-employees for services is based on the value of the services provided or the fair value of the shares issued. The measurement of non-employee stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. The Company expensed its share-based compensation for share-based payments granted under the accelerated method, which treats each vesting tranche as if it were an individual grant. The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors and non-employee contractors, with an exercise price greater than or equal to the fair market value of Delcath’s common stock at the date of the grant. The Company estimates the fair value of stock options using an option pricing model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected post-vesting option life, the expected volatility of Delcath’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and Delcath’s expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. Income Taxes The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company classifies interest and penalty expense related to uncertain tax positions as a component of income tax expense. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in its assessment of a valuation allowance. See Note 13 for additional information. Net Loss per Common Share Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all stock options, unvested restricted stock and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2016 and 2015 are as follows: (in thousands, except share data) 2016 2015 Net loss – basic and diluted $ (17,971 ) $ (14,704 ) Net loss per share – basic and diluted (10.59 ) (14.56 ) Weighted average shares outstanding – basic and diluted 1,696,237 1,010,105 For the years ended December 31, 2016 and 2015, the following potentially dilutive securities were excluded from the computation of diluted earnings per share (EPS) because their effects would be antidilutive. Shares excluded from the computation of diluted EPS: 2016 2015 Stock options 41,356 47,221 Unvested restricted shares 18,993 35,955 Warrants 7,216,020 1,128,688 Total 7,276,369 1,211,864 All share numbers presented in this footnote reflect a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016. Segment Information The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. A single management team that reports to the CEO and President comprehensively manages the business. Accordingly, the Company does not have separately reportable segments. Foreign Currency and Currency Translation Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement of operations. The assets and liabilities of the Company’s international subsidiaries are translated from their functional currencies into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive income. Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company intends to adopt this standard on January 1, 2018 and does not anticipate that this guidance will materially impact its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the ASU (1) provides a definition of the term substantial doubt, (2) requires an evaluation every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) requires an express statement and other disclosures when substantial doubt is not alleviated, and (6) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This standard is effective for the fiscal years ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company has adopted this guidance. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. ASU 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company intends to adopt this standard on January 1, 2017 and does not anticipate that this guidance will materially impact its consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). ASU 2015-17 requires deferred tax liabilities and assets to be classified as non-current on the consolidated balance sheet. ASU 2015-17 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years and early application is permitted. ASU 2015-17 may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The Company intends to adopt this standard on January 1, 2017 and does not anticipate that this guidance will materially impact its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is currently evaluating the impact it may have on its consolidated financial statements In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. As of December 31, 2016, the Company has early adopted ASU 2016-09. The cumulative-effect adjustment to equity related to the recognition of excess tax benefits (offset by valuation allowance) is discussed in Note 13. In June 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The ASU is effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including interim periods within those fiscal years. An entity that elects early adoption must adopt all of the amendments in the same period. The guidance requires application using a retrospective transition method. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and early adoption is permitted. The Company intends to adopt this standard on January 1, 2018 and is evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventories	(4) Inventories Inventories consist of: (in thousands) December 31, 2016 December 31, 2015 Raw materials $ 346 $ 360 Work-in-process 214 251 Finished goods 100 146 Total Inventory $ 660 $ 757

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2016
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses And Other Current Assets	(5) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets include the following: (in thousands) December 31, 2016 December 31, 2015 Insurance premiums $ 501 $ 625 Kits for clinical use — 162 Other 197 173 Total prepaid expenses and other current assets $ 698 $ 960 Other consists of various prepaid expenses and other current assets, with no individual item accounting for more than 5% at December 31, 2016 and 2015.

Property, Plant, and Equipment

Property, Plant, and Equipment	12 Months Ended
	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Property, Plant, and Equipment	(6) Property, Plant, and Equipment Property, plant, and equipment consists of: (in thousands) December 31, 2016 December 31, 2015 Buildings and land $ 556 $ 556 Enterprise hardware and software 1,532 1,520 Leaseholds 1,504 1,305 Equipment 940 902 Furniture 354 355 Property, plant and equipment, gross 4,886 4,638 Accumulated depreciation (3,803 ) (3,506 ) Property, plant and equipment, net $ 1,083 $ 1,132 Depreciation expense for the years ended December 31, 2016 and 2015 was $0.3 million and $0.6 million, respectively.

Current Accrued Expenses

Current Accrued Expenses	12 Months Ended
	Dec. 31, 2016
Payables And Accruals [Abstract]
Current Accrued Expenses	(7) Current Accrued Expenses Current accrued expenses include the following: (in thousands) December 31, 2016 December 31, 2015 Clinical trial expenses $ 1,365 $ 692 Compensation, excluding taxes 933 391 Professional fees 286 220 Short-term portion of lease restructuring 216 219 Other 607 721 Total accrued expenses $ 3,407 $ 2,243 Other consists of various accrued expenses, with no individual item accounting for more than 5% of current liabilities at December 31, 2016 and 2015.

Restructuring Expenses

Restructuring Expenses	12 Months Ended
	Dec. 31, 2016
Restructuring And Related Activities [Abstract]
Restructuring Expenses	(8) Restructuring Expenses In order to help reduce operating costs and more appropriately align its office space with the reduced size of its workforce, the Company entered into two sub-leases for office space at its 810 Seventh Avenue office. On May 22, 2014, the Company entered into a sub-lease agreement (“Sub-lease #1”) for approximately one-half of the office space at this location (“Suite 3500”), resulting in a lease restructuring reserve of approximately $0.9 million. On August 18, 2014, the Company entered into a sub-lease agreement (“Sub-lease #2”) for the remaining one-half of office space at its 810 Seventh Avenue office (“Suite 3505”), resulting in a lease restructuring reserve of approximately $0.7 million. As of December 31, 2016, the total remaining lease restructuring liability for its leased office space was approximately $0.8 million, of which approximately $0.2 million and $0.6 million were included in Accrued expenses and Other non-current liabilities on the consolidated balance sheets, respectively. The following table provides the year-to-date activity of the Company’s restructuring reserves as of December 31, 2016: (in thousands) Lease Liability Reserve balance at December 31, 2015 $ 1,039 Charges — Payments/Utilizations (219 ) Reserve balance at December 31, 2016 $ 820

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Convertible Notes Payable	(9) Convertible Notes Payable On June 6, 2016, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain investors named on the Schedule of Buyers attached to the SPA pursuant to which the Company issued $35.0 million in principal face amount of senior secured convertible notes of the Company (the “Notes”) and related Series C Warrants (the “Series C Warrants”) to purchase additional shares of the Company’s common stock, par value $0.01 per share (“Common Stock”). $35.0 million of the Notes were issued for cash proceeds of $32.2 million with an original issue discount in the amount of $2.8 million. The Notes are secured pursuant to a Security Agreement which creates a first priority security interest in all of the personal property (other than Excluded Collateral (as defined in the Security Agreement)) of the Company of every kind and description, tangible or intangible, whether currently owned and existing or created or acquired in the future. The Notes do not bear any ordinary interest. However, interest shall commence accruing immediately upon the occurrence of, and shall continue accruing during the continuance of, an Event of Default (as defined in the SPA), at 15% per annum and shall be computed on the basis of a 360-day year of twelve 30-day months and shall be payable, if applicable, in arrears for each calendar month on the first (1st) business day of each calendar month after any such interest accrues after an Event of Default. Under the terms of the Notes, at closing the Company received an initial tranche of $3.0 million for immediate use for general corporate purposes. A second tranche of $3.0 million was released to the Company in December 2016. The remaining cash proceeds of $26.2 million are being held in a restricted account and will be released to the Company in subsequent tranches subject to certain equity conditions. As security for the Company’s obligations under the Notes, $26.2 million of the total net cash proceeds is subject to a cash covenant restricting its use and requiring it to be held in a Master Restricted Account established in accordance with and pursuant to the terms and conditions of an account control agreement between the Company, the Buyers and Silicon Valley Bank (a “Controlled Account Agreement”). Subject to certain equity conditions, the $26.2 million of restricted cash will become unrestricted in equal quarterly installments during 2017, such that the balance will become unrestricted by the maturity date of the Notes, December 29, 2017, subject to satisfaction of certain equity conditions contained in the Notes. In connection with the issuance of the Notes under the SPA, the Company also issued Series C Warrants, exercisable to acquire 6.8 million shares of Common Stock. On December 31, 2017, the number of Warrant Shares issuable upon exercise of the Series C Warrants will be increased by such number of Warrant Shares equal to 75% of the difference of (i) the quotient of (A) the product of (x) the exercise price as of the date of issuance (as adjusted for certain events) multiplied by (y) the number of Warrant Shares as of the date of issuance (as adjusted for certain events), divided by (B) the volume-weighted average price of the Common Stock on the maturity date, less (ii) the number of Warrant Shares as of the date of issuance (as adjusted for certain events). Each Series C Warrant will be exercisable by the holder beginning June 13, 2017 and continuing for a period of five years thereafter. The Series C Warrants are exercisable at $4.83 per share of common stock, subject to adjustments for certain dilutive events. The provisions in the Series C Warrants require the Company to account for the warrants as derivative liabilities. The Company recognized a discount to debt of $27.8 million related to the initial fair value of the Series C Warrants. The Company has agreed to make amortization payments with respect to the Notes in fourteen (14) equal installments beginning seven (7) months after the original date of issuance of June 13, 2016 (each, an “Installment Date”). On each installment date, assuming certain equity conditions are met, the installment payment shall, at the election of the Company, automatically be converted into shares of Common Stock at a conversion rate defined in the agreement. If we cannot meet the equity conditions, we could be required to repay some or all of the amounts due under the notes in cash, and we may not have the funds available to make one or more of such payments when due. As a result of the Notes including a feature such that the conversion price is based upon a formula which includes discounts to the market price of the common stock as well as having a lower effective conversion price considering the issuance discount and the value allocated to the Series C Warrants, the Company has recognized a beneficial conversion feature of $4.4 million. The original issue discount, the beneficial conversion feature, and the fair value of the issuance of the Series C Warrants are collectively considered the debt discount. The Company recorded a debt discount in the amount of $35.0 million which is being amortized over the life of the Notes using the effective interest method. As of December 31, 2016, $14.0 million of the debt discount has been amortized to interest expense. In addition to the debt discounts listed above, the Notes also include put options in the event of default and change in control as defined in the Notes. The value of such options was zero as the probability for such events was remote as of the issuance date and at December 31, 2016. All debt issuance costs are accounted for as a deferred asset and will be amortized over the life of the Notes. As of December 31, 2016, the Company had incurred approximately $1.0 in debt issuance costs and had amortized approximately $0.3 million of those costs. The following table summarizes the convertible notes outstanding at December 31, 2016: (in thousands) December 31, 2016 Convertible notes payable, principal $ 34,351 Debt discounts (21,008 ) Net convertible note payable $ 13,343 In 2016, the Company issued 1.8 million shares as payment for $0.6 million of convertible notes payable.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Stockholders Equity Note [Abstract]
Stockholders' Equity	(10) Stockholders’ Equity Reverse Stock Split On July 19, 2016, shareholders of the Company approved, through a shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Delcath’s common stock at a ratio within a range of one-for-ten (1:10) to one-for-twenty (1:20). The reverse stock split became effective on July 21, 2016 at which time Delcath’s common stock began trading on the NASDAQ Stock Exchange on a one-for-sixteen (1:16) split-adjusted basis. All owners of record as of the open of the NASDAQ market on July 21, 2016 received one issued and outstanding share of Delcath common stock in exchange for sixteen issued and outstanding shares of Delcath common stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-sixteen exchange were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Delcath common stock, which remains at $0.01. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements contained in this Annual Report on Form 10-K and the accompanying Notes, have been restated to give retrospective presentation for the reverse stock split. In addition, shareholders of the Company also approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 170,000,000 to 500,000,000. The previously discussed reverse stock split had no impact on the increase in authorized shares. Stock and Warrant Issuances In October 2013, the Company completed the sale of 81,875 shares of its common stock and the issuance of warrants to purchase approximately 37,000 common shares (the “2013 Warrants”) pursuant to a placement agency agreement. The Company received proceeds of $7.5 million, with net cash proceeds after related expenses from this transaction of approximately $6.9 million. Of those proceeds, the Company allocated an estimated fair value of $1.9 million to the 2013 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. At December 31, 2016, the 2013 Warrants were exercisable at $112.64 per share with 36,848 warrants outstanding. The 2013 Warrants have a five-year term. In February 2015, the Company completed the sale of 153,750 shares of its common stock and the issuance of warrants to purchase 69,000 common shares (the “February 2015 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $2.6 million, with net cash proceeds after related expenses from this transaction of $2.5 million. Of those proceeds, the Company allocated an estimated fair value of $0.8 million to the February 2015 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At December 31, 2016, the February 2015 Warrants were exercisable at $1.61 per share with approximately 30,238 warrants outstanding. The February 2015 Warrants have a five-year term. There were approximately 40,000 February 2015 Warrants exercised during the year ended December 31, 2016 for proceeds of approximately $0.1 million. In July 2015, the Company completed the sale of approximately 0.6 million Units consisting of 0.6 million shares of its common stock, Series A Warrants to purchase up to approximately 0.4 million common shares (“Series A Warrants”) and Series B Warrants to purchase Units consisting of up to approximately 0.6 million common shares (“Series B Warrants”) and 0.4 million Series A Warrants pursuant to an underwriting agreement. The Company received proceeds of $7.0 million, with net cash proceeds after related expenses from this transaction of $6.0 million. Of those proceeds the Company allocated an estimated fair value of $3.4 million to the Series A and Series B Warrants. During the year ended December 31, 2016, approximately 0.1 million Series B Warrants were exercised for net proceeds of approximately $0.8 million. The remaining 0.4 million Series B Warrants expired on January 29, 2016 and the related liability was credited to Change in the fair value of the warrant liability. As a result of the Series B Warrant exercises, an additional 0.1 million Series A Warrants were issued. The exercise price of the Series A Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and is subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. At December 31, 2016, the July 2015 Series A Warrants were exercisable at $1.61 with approximately 0.3 million warrants outstanding. The Series A Warrants have a five-year term. There were approximately 0.3 million July 2015 Series A Warrants exercised during the year ended December 31, 2016 for proceeds of $0.4 million. In June 2016, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued $35.0 million in principal face amount of the Notes and related Series C Warrants to purchase 6.8 million additional shares of the Company’s common stock. The Company allocated an estimated fair value of $27.8 million to the Series C Warrants. On December 31, 2017, the number of Warrant Shares issuable upon exercise of the Series C Warrants will be increased by such number of Warrant Shares equal to 75% of the difference of (i) the quotient of (A) the product of (x) the exercise price as of the date of issuance (as adjusted for certain events) multiplied by (y) the number of Warrant Shares as of the date of issuance (as adjusted for certain events), divided by (B) the volume-weighted average price of the Common Stock on the maturity date, less (ii) the number of Warrant Shares as of the date of issuance (as adjusted for certain events). The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. At December 31, 2016, The Series C Warrants were exercisable at $4.83 with approximately 6.8 million warrants outstanding. The Series C Warrants will be exercisable by the holder beginning one year after the closing date and continuing for a period of five years thereafter. In October 2016, the Company completed the sale of 425,000 shares of its common stock and the issuance of warrants to purchase 148,750 common shares (the “October 2016 Warrants”) pursuant to an underwriting agreement. The Company received proceeds of $1.2 million, with net cash proceeds after related expenses from this transaction of $1.1 million. Of those proceeds, the Company allocated an estimated fair value of $0.3 million to the October 2016 Warrants. The exercise price is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. The exercise price of the warrants is also subject to anti-dilution adjustments for any issuance of common stock or rights to acquire common stock for consideration per share less than the exercise price of the warrants. For purposes of these adjustments, dilutive issuances do not include securities issued under existing instruments, under board-approved equity incentive plans or in certain strategic transactions. At December 31, 2016, the October 2016 Warrants were exercisable at $1.61 per share with 78,750 warrants outstanding. The October 2016 Warrants have a five-year term. There were 70,000 October 2016 Series C Warrants exercised during the year ended December 31, 2016 for proceeds of $0.1 million. In October 2015, the Company filed a registration statement on Form S-3 with the SEC, which was declared effective on October 20, 2015 and allows the Company to offer and sell, from time to time in one or more offerings, up to $77.4 million of common stock, preferred stock, warrants, debt securities and stock purchase contracts as it deems prudent or necessary to raise capital at a later date. Pursuant to SEC regulations, so long as the Company’s public float remains below $75 million, we cannot sell securities from the shelf registration statement which represent more than one third of the market value of our non-affiliated public float during any 12-month period. Stock Incentive Plans The Company established the 2004 Stock Incentive Plan and the 2009 Stock Incentive Plan (collectively, the “Plans”) under which 11,719 and 200,391 shares, respectively, have been reserved for the issuance of stock options, stock appreciation rights, restricted stock, stock grants and other equity awards. In July 2016, the total number of shares of Delcath common stock reserved for issuance under the 2009 Stock Incentive Plan was increased by 106,250 shares, from 94,141 to 200,391 shares, upon a favorable vote by the Company’s stockholders. The Plans are administered by the Compensation and Stock Option Committee of the Board of Directors which determines the individuals to whom awards shall be granted as well as the type, terms, conditions, option price and the duration of each award. As of December 31, 2016, there were 120,883 A stock option grant allows the holder of the option to purchase a share of the Company’s common stock in the future at a stated price. Options and Restricted Stock granted under the Plans vest as determined by the Company’s Compensation and Stock Option Committee. Options granted under the Plans expire over varying terms, but not more than ten years from the date of grant. Stock option activity for 2016 and 2015 is as follows: Stock Option Activity under the Plans Stock Options Exercise Share Weighted Exercise Price Weighted Average Remaining (Years) Outstanding at December 31, 2014 17,577 $19.84 - $3,921.92 $ 378.08 8.83 Granted 32,765 19.04 19.04 Forfeited (3,121 ) 19.04 - 2,713.60 480.16 Outstanding at December 31, 2015 47,221 19.04-3,921.92 $ 122.40 8.95 Granted — — — Forfeited (5,865 ) $19.04-$545.28 23.95 Outstanding at December 31, 2016 41,356 $19.84-$3,788.80 $ 135.77 7.90 Exercisable at December 31, 2016 26,774 $19.04-$3,788.80 $ 199.31 7.63 For the years ended December 31, 2016 and 2015 the Company recognized compensation expense related to stock option grants of approximately $0.2 million and $0.3 million, respectively. The estimated fair value of each option award granted was determined on the date of grant using an option pricing model with the following assumptions for option grants during the year ended December 31, 2015. There were no option grants during the year ended December 31, 2016: Year ended December 31, 2015 Weighted average risk-free interest rates 1.82 % Weighted average expected volatility 97.70 % Dividend yield — Weighted average expected option term (in years) 5.15 Weighted average grant date fair value $ 0.89 No dividend yield was assumed because the Company has never paid a cash dividend on its common stock and does not expect to pay dividends in the foreseeable future. Volatilities were developed using the Company’s historical volatility. The risk-free interest rate was developed using the U.S. Treasury yield for periods equal to the expected life of the stock options on the grant date. The expected option term for grants made during 2015, 2014, 2013 and the second half of 2012 is based on actual historical results. The expected option term for grants made prior to that was developed based on the mid-point between the vesting date and the expiration date of each respective grant as permitted under ASC 718. This method of determining the expected holding period was utilized because the Company did not have sufficient historical experience from which to estimate the period. A summary of the Company’s non-vested options to purchase shares as of December 31, 2016 and changes during the year ended December 31, 2016 and December 31, 2015 are presented below: Non-Vested Options Number of Options Weighted Average Exercise Price Non-vested at January 1, 2015 14,116 $ 332.16 Granted 32,765 28.48 Vested (9,994 ) 421.60 Forfeited (1,416 ) 574.72 Non-vested at December 31, 2015 35,471 $ 22.55 Granted — — Vested (15,671 ) 26.85 Forfeited (5,218 ) 19.23 Non-vested at December 31, 2016 14,582 $ 19.11 Additional compensation expense of approximately $55,000, relating to the unvested portion of stock options granted, is expected to be recognized over a remaining average period of 1.06 years. The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2016 is $0. The aggregate intrinsic value represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s closing stock price of $0.92 as of December 31, 2016, which would have been received by the option holders had those option holders exercised their options as of that date. A summary of the Company’s restricted stock activity as of December 31, 2016 and changes during the year ended December 31, 2016 and December 31, 2015 are presented below: Restricted Stock Activity Number of Shares Weighted Average Grant Date Fair Value Non-vested at January 1, 2015 1,857 $ 269.44 Granted 36,000 41.60 Vested (1,854 ) 217.60 Forfeited (8 ) 54.40 Non-vested at December 31, 2015 35,995 $ 19.04 Granted 4,687 4.32 Vested (19,189 ) 15.44 Forfeited (2,500 ) 19.04 Non-vested at December 31, 2016 18,993 $ 19.04 For the years ended December 31, 2016 and 2015 the Company recognized compensation expense related to restricted stock grants of approximately $0.3 million and $0.3 million, respectively. Additional compensation expense of $0.1 million relating to the unvested portion of restricted stock granted is expected to be recognized over a remaining average period of 1.12 years. Warrants The Company issued warrants as part of its offerings in 2013, 2015, and 2016, as well as part of its issuance of convertible notes in 2016. A summary of warrant activity is as follows: Warrants Exercise per Share Weighted Average Exercise Price Weighted Average Remaining Life (Years) Outstanding at January 1, 2014 53,134 28.00-112.64 $ 86.69 2.78 Issued 1,091,844 12.80 Exercised (13,457 ) 13.12 Expired (2,833 ) 13.12 Outstanding at December 31, 2015 1,128,688 11.84-112.64 $ 16.02 2.16 Issued 7,031,929 4.80 Exercised (499,633 ) 2.75 Expired (444,964 ) 5.68 Outstanding at December 31, 2016 7,216,020 1.61-112.64 $ 5.20 5.59

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	(11) Fair Value Measurements Derivative Financial Instruments As disclosed in Note 10 of the Company’s consolidated financial statements contained in this Annual Report on Form 10-K, the Company allocated part of the proceeds of public offerings in 2013, 2015 and 2016 of the Company’s common stock to warrants issued in connection with those transactions. In addition, the Company recognized a discount to debt related to the initial fair value of warrants issued in connection with the June 2016 Convertible Notes discussed in further detail in Note 9 of the Company’s consolidated financial statements contained in this Annual Report on Form 10-K. The valuations of the October 2013, February 2015, July 2015 Series A, June 2016 Series C, and October 2016 Warrants (collectively, the “Warrants”) were determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. The Company has classified the Warrants as a current liability due to certain provisions relating to price adjustments and potential cash payments, as well as the holders’ ability to exercise the warrants within twelve months of the reporting date and has accounted for them as derivative instruments in accordance with ASC 815, adjusting the fair value at the end of each reporting period. Additionally, the Company has determined that the warrant derivative liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing models against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of Delcath stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Delcath’s stock over that term; annual rate of dividends; and the risk-free rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of Delcath stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The risk-free rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, Delcath determined the warrant derivative liability is most appropriately classified within Level 3 of the fair value hierarchy. For the year ended December 31, 2016, the Company recorded pre-tax derivative instrument income of $12.8 million. The resulting derivative instrument liabilities totaled $18.8 million at December 31, 2016. Management expects that the Warrants will either be exercised or expire worthless. The fair value of the Warrants at December 31, 2016 was determined by using option pricing models assuming the following: October 2016 Warrants June 2016 Series C Warrants July 2015 Series A Warrants February 2015 Warrants October 2013 Warrants Expected volatility 95.03% 94.19% 95.51% 95.52% 152.70% Risk free interest rates 1.93% 2.01% 1.59% 1.47% 1.20% Expected life (in years) 4.80 5.50 3.60 3.10 1.80 The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2016 and 2015, aggregated by the level in the fair value hierarchy within which those measurements fall. Assets and Liabilities Measured at Fair Value on a Recurring Basis Assets and Liabilities Measured at Fair Value on a Recurring Basis Level 1 Level 2 Level 3 Balance at December 31, (in thousands) 2016 2015 2016 2015 2016 2015 2016 2015 Liabilities Derivative instrument liabilities $ — $ — $ — $ — $ 18,751 $ 3,785 $ 18,751 $ 3,785 Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (in thousands) Warrant Liability Balance at January 1, 2015 $ 225 Total change in the liability included in earnings (564 ) Fair value of warrants issued 4,247 Fair value of warrants exercised (123 ) Balance at December 31, 2015 3,785 Total change in the liability included in earnings (12,780 ) Fair value of warrants issued 28,472 Fair value of warrants exercised (726 ) Balance at December 31, 2016 $ 18,751

Commitments

Commitments	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments	(12) Commitments Operating Leases In February 2010, the Company entered into an agreement to lease (Initial Lease) 8,629 square feet of office space at 810 Seventh Avenue, New York, NY with an option to expand an additional 8,629 square feet. The term of the Initial Lease began in March, 2010. In September 2010, the Company exercised its option right under the Initial Lease and entered into an agreement to lease (Lease Amendment) an additional 8,629 square feet of office space. The term of the Lease Amendment began in January 2011 and will expire in March 2021. In addition, the Lease Amendment extends the term of the Initial Lease to March 2021. The Initial Lease and the Lease Amendment provide for annual rent of $996,000 in 2015, $1.0 million in 2016, and $1.1 million in 2017-2020. As discussed in Note 8, the Company has sub-leased this office space. In August 2011, Delcath Systems Limited entered into an agreement of lease for an office and manufacturing facility located in the city of Galway, Ireland. This facility is approximately 19,200 square feet and is intended to be the location of Delcath’s European headquarters. The Lease is for a term of ten years, commencing August 2, 2011. The Lease provides for fixed annual lease amounts payable in advance in equal quarterly installments. The annual lease amounts, which escalate annually, are as follows (USD conversions are based on the December 31, 2016 conversion rate): Year 1 – €106,051 ($115,458), Year 2 – €134,974 ($146,946), Year 3 – €159,077 ($173,187) and Years 4 and 5 – €183,179 ($199,427). Annual lease amounts in years 6 through 10 are to be paid at a fixed amount of €187,209 ($197,377). Delcath Limited is also required to pay for customary building operating expenses. Delcath Limited’s payment obligations and performance of the Lease are guaranteed by Delcath. The Company has sub-leased a portion of this facility. In March 2016, the Company entered into a sub-lease agreement to lease approximately 6,877 square feet of office space at 1633 Broadway, New York, NY. The term began in April 2016 and is effective through March 2019. The agreement provides for total annual base rent of $522,652. In October 2016, the Company entered into a lease agreement for 95-97 Park Road in Queensbury, NY, agreeing to lease the 6,000 square feet at that location. The term began on November 1, 2016 and was effective for a two year period. The agreement provides for total annual base rent of $48,223 and will expire October 2018. Future minimum lease payments, net of receipts due under the terms of subleases, under all operating leases at December 31, 2016 are as follows: (in thousands) Future Payment 2017 $ 952 2018 946 2019 529 2020 428 2021 254 2022 — $ 3,109 Rent expense totaled approximately $0.5 million and $0.4 million, for the years ended December 31, 2016 and 2015, respectively. Letters of Credit Under the terms of the lease agreement for office space at 810 Seventh Avenue, New York, NY, the Company is required to maintain a letter of credit in the amount of $881,297 which will expire in February 2017 if not renewed by the Company. Under the terms of a sub-lease agreement for office space at 1633 Broadway, New York, NY, the Company is required to maintain a letter of credit in the amount of $130,663 which will expire with the sublease in March 2019.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	(13) Income Taxes There is no income tax provision for the years ended December 31, 2016 and 2015. Income before income taxes consists of: Year Ended December 31, (in thousands) 2016 2015 Domestic $ (13,930 ) $ (11,276 ) Foreign (4,040 ) (3,428 ) Income before taxes $ (17,970 ) $ (14,704 ) The provision for income taxes differs from the amount computed by applying the statutory rate as follows: Year Ended December 31, (in thousands) 2016 2015 Income taxes using U.S federal statutory rate $ (6,110 ) $ (4,999 ) Loss of tax benefit of net operating loss carryforwards 68,795 — Loss of tax benefit of state net operating loss carryforwards 13,891 — Loss of tax benefit of tax credit carryforwards 4,023 — Amortization of gain on IP migration 767 767 State income taxes, net of federal benefit (2,576 ) 380 Foreign rate differential 1,141 920 Valuation allowance (75,407 ) 2,649 Derivative charge (4,345 ) (192 ) Stock option exercises and cancellations 53 674 Research and development costs (250 ) (199 ) Other 18 — $ — $ — Significant components of the Company’s deferred tax assets are as follows: (in thousands) December 31, 2016 December 31, 2015 Deferred tax assets: Employee compensation accruals $ 1,386 $ 1,279 Accrued liabilities 343 633 Research tax credits 22 3,796 Other 55 66 Net operating losses 6,194 77,906 Total deferred tax assets $ 8,000 $ 83,680 Deferred tax liabilities: Beneficial conversion feature 906 — Total deferred tax liabilities $ 906 $ — Valuation allowance 7,094 83,680 Net deferred tax assets $ — $ — As of December 31, 2016 and 2015, the Company had net operating loss carryforwards for U.S. federal income tax purposes of approximately $209.3 million and $184.5 million, respectively. A significant portion of the federal amount, $201.0 million, is subject to an annual limitation of approximately $72,500 as a result of a change in the Company’s ownership in May 2003 and November 2016, as defined by Federal Internal Revenue Code Section 382 and the related income tax regulations. As a result of the limitations caused by the May 2003 and November 2016 ownership changes, approximately $205.7 million of the total net operating loss carryforwards is expected to expire unutilized and will be unavailable to offset future federal taxable income. Approximately $3.6 million of net operating loss carryforwards remains available to offset future federal taxable income which will expire between 2018 and 2036. In addition, the Company’s state net operating losses are also subject to annual limitations that generally follow the federal Section 382 provisions, adjusted for each state’s respective income apportionment percentages. As of December 31, 2016 and 2015, the Company had net operating loss carryforwards for state and city income tax purposes between approximately $27.3 million and $153.0 million and between approximately $27.3 million and $109.7, respectively, which expire through 2036. As a result of the 382 limitations, approximately $150.2 million and $130.5 million of New York State and New York City net operating losses are expected to expire unutilized and will be unavailable to offset future taxable income. Approximately $2.8 million and $2.7 million of net operating loss carryforwards, respectively, will be available to offset future state and city taxable income. As of December 31, 2016 and 2015, the Company had a net operating loss carryforward for foreign income tax purposes of $21.1 million and $22.1 million, respectively, which have indefinite carryforward periods. As of December 31, 2016 and 2015, the Company had federal research and development tax credit carryforwards of approximately $4.0 million and $3.8 million, respectively, which expire through 2036. As a result of the section 382 limitation, the entire tax credit carryforward is expected to expire unutilized. The Company has a tax benefit of approximately $1.0 million related to the exercise of non-qualified stock options. As a result of the adoption of ASU 2016-09, the $1.0 million tax benefit was recognized as a cumulative adjustment to retained earnings, offset by a $1 million valuation allowance against retained earnings. Management has established a 100% valuation allowance against the deferred tax assets as management does not believe it is more likely than not that these assets will be realized. The Company’s valuation allowance decreased by approximately $76.6 million and increased by approximately $2.6 million in 2016 and 2015, respectively. The primary reason for the significant decrease in the valuation allowance during the current year is due to the reduction of recognizable deferred tax assets related net operating loss and credit carryforwards resulting from the Sec. 382 ownership change. The change in valuation allowance is as follows: (in thousands) December 31, 2016 December 31, 2015 Beginning balance $ 83,680 $ 81,223 Charged to costs and expenses (75,407 ) 2,649 Charged to additional paid-in capital (1,854 ) - Charged to retained earnings 1,010 - Charged to other comprehensive income (335 ) (192 ) Ending balance $ 7,094 $ 83,680 The Company complies with the provisions of ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10. The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The Company is currently under examination by the Internal Revenue Service for the period ending December 31, 2013. The examination commenced in the third quarter of 2015 and as of December 31, 2016, there have been no adjustments proposed. The Company has not recorded an uncertain tax position and therefore a table of unrecognized tax benefits has not been presented, and no interest or penalties have been accrued as of December 31, 2016. The Company's total amount of unrecognized tax benefits could increase within the next twelve months as a result of the exam. However, the effect of the outcome cannot be reasonably estimated as the IRS examination is ongoing. The Company has not been audited by any state tax authorities in connection with income taxes. The Company has not been audited by international tax authorities or any states in connection with income taxes. The Company’s New York State tax returns have been subject to annual desk reviews which have resulted in insignificant adjustments to the related franchise tax liabilities and credits. The Company is no longer subject to federal and state examination for tax years ending prior to December 31, 2013; tax years ending December 31, 2013 through December 31, 2016 remain open to examination. However, the Company’s tax years December 31, 1998 through December 31, 2016 generally remain open to adjustment for all federal, state and foreign tax matters until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization, and the applicable statutes of limitation have expired in the utilization year. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. Delcath recognizes interest accrued related to unrecognized tax benefits and penalties, if incurred, as a component of income tax expense.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	(14) Subsequent Events NASDAQ Notification Letter On February 13, 2017, the Company received a notification letter (the “Notice”) from The NASDAQ Stock Market (“NASDAQ”) advising the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The NASDAQ Capital Market pursuant to NASDAQ Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Notice stated that the Company will be provided 180 calendar days, or until August 14, 2017, to regain compliance with the Minimum Bid Price Rule. To do so, the bid price of the Company’s common stock must close at or above $1.00 per share for a minimum of ten consecutive business days prior to that date. If, by August 14, 2017 the Company cannot demonstrate compliance with Marketplace Rule 5550(a)(2), then the NASDAQ staff will determine whether or not the Company meets The NASDAQ Capital Market initial listing criteria set forth in NASDAQ Marketplace Rule 5550, except for the bid price requirement. If the Company meets the initial listing criteria (with the exception of the bid price requirement) and provides written notice of its intention to cure the deficiency during an additional 180 calendar day compliance period, the NASDAQ staff will notify the Company that it has been granted such an additional compliance period (the “second compliance period”). If the Company is not eligible for the second compliance period, the NASDAQ staff will provide written notice that the Company’s securities will be delisted. At that time, the Company may appeal the NASDAQ staff’s determination to delist its securities to a Listing Qualifications Panel. From January 1, 2017 through March 28, 2017, the Company issued 109,345,554 shares of Common Stock to the holders of the Notes as payment on the convertible notes payable. From January 1, 2017 through March 28, 2017, the holders of Notes released an aggregate of approximately $6.6 million in cash previously funded to the Company and authorized the release of those funds from the restricted accounts of the Company in accordance with the Master Control Account Agreement.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s consolidated balance sheets and the amount of revenues and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for derivative instrument liabilities, stock-based compensation, valuation of inventory, impairment of long-lived assets, income taxes and operating expense accruals. Such assumptions and estimates are subject to change in the future as additional information becomes available or as circumstances are modified. Actual results could differ from these estimates.
Cash Equivalents and Concentrations of Credit Risk	Cash Equivalents and Concentrations of Credit Risk The Company considers investments with original maturities of three months or less at date of acquisition to be cash equivalents. The Company has deposits that exceed amounts insured by the Federal Deposit Insurance Corporation (FDIC), however, the Company does not consider this a significant concentration of credit risk based on the strength of the financial institution.
Restricted Cash	Restricted Cash Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on the accompanying consolidated balance sheets. On June 13, 2016, the Company issued $35.0 million in senior secured convertible notes and received $32.2 million in cash proceeds. Under the terms of the notes, at closing, an initial tranche of $3.0 million was available for immediate use by the Company for general corporate purposes. The remaining cash proceeds of $29.2 million were available in a tranche of $3.0 million on December 29, 2016 (“First Release Date”) and the remainder of $26.2 million will be available in four equal tranches to be released quarterly, beginning in February 2017 (“Subsequent Release Dates”), pursuant to an account control agreement whereby the restrictions on the proceeds are terminated when the Company meets certain equity conditions. The terms of the Notes are discussed in more detail in Note 9 contained in this Annual Report on Form 10-K. The cash is deposited in an account that is not FDIC insured.
Accounts Receivable	Accounts Receivable Accounts receivable, principally trade, are generally due within 30 days and are stated at amounts due from customers. Collections and payments from customers are monitored and a provision for estimated credit losses may be created based upon historical experience and specific customer collection issues that may be identified.
Inventories	Inventories Inventories are valued at the lower of cost or market value using the first-in, first-out method. The reported net value of inventory includes finished saleable products, work-in-process, and raw materials that will be sold or used in future periods. The Company reserves for expired, obsolete, and slow-moving inventory. Prior to obtaining authorization to affix the CE Mark to its Generation Two CHEMOSAT System in April 2012, the Company expensed all of its inventory costs as research and development. Inventory as of December 31, 2016 includes finished goods and components that have been purchased since April 2012. Therefore, to the extent that materials expensed prior to April 2012 are used in manufacturing finished goods for sale, the Company’s cost of goods sold will be impacted accordingly.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are recorded at cost, less accumulated depreciation. The Company provides for depreciation on a straight line basis over the estimated useful lives of the assets which range from three to seven years. Leasehold improvements will be amortized over the shorter of the lease term or the estimated useful life of the related assets when they are placed into service. Maintenance and repairs are charged to operations as incurred. Expenditures which substantially increase the useful lives of the related assets are capitalized.
Derivative Instrument Liability	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of the hedging relationship designation. Accounting for changes in the fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2016 and 2015, the Company did not have any derivative instruments that were designated as hedges.
Fair Value Measurements	Fair Value Measurements The Company adheres to ASC 820, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 applies to reported balances that are required or permitted to be measured at fair value under existing accounting pronouncements; accordingly, the standard does not require any new fair value measurements of reported balances. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). • Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. • Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. • Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.
Revenue Recognition	Revenue Recognition Revenue from product sales is generally recognized when all of the following criteria have been met: persuasive evidence of an arrangement exists; delivery has occurred; product price is fixed or determinable; and collection of the resulting receivable is reasonably assured. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied.
Deferred Revenue	Deferred Revenue Deferred revenue on the accompanying consolidated balance sheets includes payment received for product sales to a distributor. When obligations or contingencies remain after the products are shipped, such as training and certifying the treatment centers, revenue is deferred until the obligations or contingencies are satisfied. The Company will recognize the revenue related to product sales when its obligations under the agreement have been satisfied.
Selling, General and Administrative	Selling, General and Administrative Selling, general and administrative costs include personnel costs and related expenses for the Company’s sales, marketing, general management and administrative staff, recruitment, costs related to the Company’s commercialization efforts in Europe, professional service fees, professional license fees, business development and certain general legal activities. All such costs are charged to expense when incurred.
Research and Development	Research and Development Research and development costs include the costs of materials used for clinical trials and R&D, personnel costs associated with device and pharmaceutical R&D, clinical affairs, medical affairs, medical science liaisons, and regulatory affairs, costs of outside services and applicable indirect costs incurred in the development of the Company’s proprietary drug delivery system. All such costs are charged to expense when incurred.
Stock Based Compensation	Stock Based Compensation The Company accounts for its share-based compensation in accordance with the provisions of ASC 718, which establishes accounting for equity instruments exchanged for employee services and ASC 505-50, which establishes accounting for equity-based payments to non-employees. Under the provisions of ASC 718, share-based compensation is measured at the grant date, based upon the fair value of the award, and is recognized as an expense over the option holders’ requisite service period (generally the vesting period of the equity grant). The Company is required to record compensation cost for all share-based payments granted to employees based upon the grant date fair value, estimated in accordance with the provisions of ASC 718. Under the provisions of ASC 505-50, measurement of compensation cost related to common shares issued to non-employees for services is based on the value of the services provided or the fair value of the shares issued. The measurement of non-employee stock-based compensation is subject to periodic adjustment as the underlying equity instrument vests. The Company expensed its share-based compensation for share-based payments granted under the accelerated method, which treats each vesting tranche as if it were an individual grant. The Company periodically grants stock options for a fixed number of shares of common stock to its employees, directors and non-employee contractors, with an exercise price greater than or equal to the fair market value of Delcath’s common stock at the date of the grant. The Company estimates the fair value of stock options using an option pricing model. Key inputs used to estimate the fair value of stock options include the exercise price of the award, the expected post-vesting option life, the expected volatility of Delcath’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and Delcath’s expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards.
Income Taxes	Income Taxes The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company classifies interest and penalty expense related to uncertain tax positions as a component of income tax expense. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in its assessment of a valuation allowance. See Note 13 for additional information.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all stock options, unvested restricted stock and warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2016 and 2015 are as follows: (in thousands, except share data) 2016 2015 Net loss – basic and diluted $ (17,971 ) $ (14,704 ) Net loss per share – basic and diluted (10.59 ) (14.56 ) Weighted average shares outstanding – basic and diluted 1,696,237 1,010,105 For the years ended December 31, 2016 and 2015, the following potentially dilutive securities were excluded from the computation of diluted earnings per share (EPS) because their effects would be antidilutive. Shares excluded from the computation of diluted EPS: 2016 2015 Stock options 41,356 47,221 Unvested restricted shares 18,993 35,955 Warrants 7,216,020 1,128,688 Total 7,276,369 1,211,864 All share numbers presented in this footnote reflect a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016.
Segment Information	Segment Information The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. A single management team that reports to the CEO and President comprehensively manages the business. Accordingly, the Company does not have separately reportable segments.
Foreign Currency and Currency Translation	Foreign Currency and Currency Translation Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses)/gains in the statement of operations. The assets and liabilities of the Company’s international subsidiaries are translated from their functional currencies into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive income.
Recently Adopted Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”) that updates the principles for recognizing revenue. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for the Company beginning in its fiscal year 2018, and may be applied retrospectively to all prior periods presented or through a cumulative adjustment to the opening retained earnings balance in the year of adoption. The Company intends to adopt this standard on January 1, 2018 and does not anticipate that this guidance will materially impact its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements — Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the ASU (1) provides a definition of the term substantial doubt, (2) requires an evaluation every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) requires an express statement and other disclosures when substantial doubt is not alleviated, and (6) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This standard is effective for the fiscal years ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company has adopted this guidance. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. ASU 2015-11 more closely aligns the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards by requiring companies using the first-in, first-out and average costs methods to measure inventory using the lower of cost and net realizable value, where net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. ASU 2015-11 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. ASU 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company intends to adopt this standard on January 1, 2017 and does not anticipate that this guidance will materially impact its consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740). ASU 2015-17 requires deferred tax liabilities and assets to be classified as non-current on the consolidated balance sheet. ASU 2015-17 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years and early application is permitted. ASU 2015-17 may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The Company intends to adopt this standard on January 1, 2017 and does not anticipate that this guidance will materially impact its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases, which requires entities to report a right-to-use asset and liability for the obligation to make payments for all leases with the exception of those leases with a term of twelve months or less. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018. The Company intends to adopt this standard on January 1, 2019 and is currently evaluating the impact it may have on its consolidated financial statements In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. As of December 31, 2016, the Company has early adopted ASU 2016-09. The cumulative-effect adjustment to equity related to the recognition of excess tax benefits (offset by valuation allowance) is discussed in Note 13. In June 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The ASU is effective for public companies for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including interim periods within those fiscal years. An entity that elects early adoption must adopt all of the amendments in the same period. The guidance requires application using a retrospective transition method. The Company is currently evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The new guidance requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. ASU 2016-18 is effective for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years, and early adoption is permitted. The Company intends to adopt this standard on January 1, 2018 and is evaluating the effects, if any, that the adoption of this guidance will have on the Company’s financial statements.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Calculation of net loss and number of shares used to compute basic and diluted earnings per share	The calculation of net loss and the number of shares used to compute basic and diluted earnings per share for the years ended December 31, 2016 and 2015 are as follows: (in thousands, except share data) 2016 2015 Net loss – basic and diluted $ (17,971 ) $ (14,704 ) Net loss per share – basic and diluted (10.59 ) (14.56 ) Weighted average shares outstanding – basic and diluted 1,696,237 1,010,105
Shares excluded from the computation of diluted EPS	Shares excluded from the computation of diluted EPS: 2016 2015 Stock options 41,356 47,221 Unvested restricted shares 18,993 35,955 Warrants 7,216,020 1,128,688 Total 7,276,369 1,211,864

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Schedule of inventories	Inventories consist of: (in thousands) December 31, 2016 December 31, 2015 Raw materials $ 346 $ 360 Work-in-process 214 251 Finished goods 100 146 Total Inventory $ 660 $ 757

Prepaid Expenses and Other Cu26

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets include the following: (in thousands) December 31, 2016 December 31, 2015 Insurance premiums $ 501 $ 625 Kits for clinical use — 162 Other 197 173 Total prepaid expenses and other current assets $ 698 $ 960

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Components of property, plant and equipment	Property, plant, and equipment consists of: (in thousands) December 31, 2016 December 31, 2015 Buildings and land $ 556 $ 556 Enterprise hardware and software 1,532 1,520 Leaseholds 1,504 1,305 Equipment 940 902 Furniture 354 355 Property, plant and equipment, gross 4,886 4,638 Accumulated depreciation (3,803 ) (3,506 ) Property, plant and equipment, net $ 1,083 $ 1,132

Current Accrued Expenses (Table

Current Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Payables And Accruals [Abstract]
Schedule of current accrued expenses	Current accrued expenses include the following: (in thousands) December 31, 2016 December 31, 2015 Clinical trial expenses $ 1,365 $ 692 Compensation, excluding taxes 933 391 Professional fees 286 220 Short-term portion of lease restructuring 216 219 Other 607 721 Total accrued expenses $ 3,407 $ 2,243

Restructuring Expenses (Tables)

Restructuring Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Restructuring And Related Activities [Abstract]
Schedule of restructuring and related costs	The following table provides the year-to-date activity of the Company’s restructuring reserves as of December 31, 2016: (in thousands) Lease Liability Reserve balance at December 31, 2015 $ 1,039 Charges — Payments/Utilizations (219 ) Reserve balance at December 31, 2016 $ 820

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Summary of Convertible Notes Outstanding	The following table summarizes the convertible notes outstanding at December 31, 2016: (in thousands) December 31, 2016 Convertible notes payable, principal $ 34,351 Debt discounts (21,008 ) Net convertible note payable $ 13,343

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Stockholders Equity Note [Abstract]
Stock option activity	Stock option activity for 2016 and 2015 is as follows: Stock Option Activity under the Plans Stock Options Exercise Share Weighted Exercise Price Weighted Average Remaining (Years) Outstanding at December 31, 2014 17,577 $19.84 - $3,921.92 $ 378.08 8.83 Granted 32,765 19.04 19.04 Forfeited (3,121 ) 19.04 - 2,713.60 480.16 Outstanding at December 31, 2015 47,221 19.04-3,921.92 $ 122.40 8.95 Granted — — — Forfeited (5,865 ) $19.04-$545.28 23.95 Outstanding at December 31, 2016 41,356 $19.84-$3,788.80 $ 135.77 7.90 Exercisable at December 31, 2016 26,774 $19.04-$3,788.80 $ 199.31 7.63
Assumptions used to determine estimated fair value of stock options granted	The estimated fair value of each option award granted was determined on the date of grant using an option pricing model with the following assumptions for option grants during the year ended December 31, 2015. There were no option grants during the year ended December 31, 2016: Year ended December 31, 2015 Weighted average risk-free interest rates 1.82 % Weighted average expected volatility 97.70 % Dividend yield — Weighted average expected option term (in years) 5.15 Weighted average grant date fair value $ 0.89
Summary of non-vested options	A summary of the Company’s non-vested options to purchase shares as of December 31, 2016 and changes during the year ended December 31, 2016 and December 31, 2015 are presented below: Non-Vested Options Number of Options Weighted Average Exercise Price Non-vested at January 1, 2015 14,116 $ 332.16 Granted 32,765 28.48 Vested (9,994 ) 421.60 Forfeited (1,416 ) 574.72 Non-vested at December 31, 2015 35,471 $ 22.55 Granted — — Vested (15,671 ) 26.85 Forfeited (5,218 ) 19.23 Non-vested at December 31, 2016 14,582 $ 19.11
Summary of restricted stock activity	A summary of the Company’s restricted stock activity as of December 31, 2016 and changes during the year ended December 31, 2016 and December 31, 2015 are presented below: Restricted Stock Activity Number of Shares Weighted Average Grant Date Fair Value Non-vested at January 1, 2015 1,857 $ 269.44 Granted 36,000 41.60 Vested (1,854 ) 217.60 Forfeited (8 ) 54.40 Non-vested at December 31, 2015 35,995 $ 19.04 Granted 4,687 4.32 Vested (19,189 ) 15.44 Forfeited (2,500 ) 19.04 Non-vested at December 31, 2016 18,993 $ 19.04
Summary of warrant activity	A summary of warrant activity is as follows: Warrants Exercise per Share Weighted Average Exercise Price Weighted Average Remaining Life (Years) Outstanding at January 1, 2014 53,134 28.00-112.64 $ 86.69 2.78 Issued 1,091,844 12.80 Exercised (13,457 ) 13.12 Expired (2,833 ) 13.12 Outstanding at December 31, 2015 1,128,688 11.84-112.64 $ 16.02 2.16 Issued 7,031,929 4.80 Exercised (499,633 ) 2.75 Expired (444,964 ) 5.68 Outstanding at December 31, 2016 7,216,020 1.61-112.64 $ 5.20 5.59

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Schedule of fair value of the warrants	The fair value of the Warrants at December 31, 2016 was determined by using option pricing models assuming the following: October 2016 Warrants June 2016 Series C Warrants July 2015 Series A Warrants February 2015 Warrants October 2013 Warrants Expected volatility 95.03% 94.19% 95.51% 95.52% 152.70% Risk free interest rates 1.93% 2.01% 1.59% 1.47% 1.20% Expected life (in years) 4.80 5.50 3.60 3.10 1.80
Assets and liabilities measured at fair value on a recurring basis	The table below presents the Company’s assets and liabilities measured at fair value on a recurring basis as of December 31, 2016 and 2015, aggregated by the level in the fair value hierarchy within which those measurements fall. Assets and Liabilities Measured at Fair Value on a Recurring Basis Assets and Liabilities Measured at Fair Value on a Recurring Basis Level 1 Level 2 Level 3 Balance at December 31, (in thousands) 2016 2015 2016 2015 2016 2015 2016 2015 Liabilities Derivative instrument liabilities $ — $ — $ — $ — $ 18,751 $ 3,785 $ 18,751 $ 3,785
Fair value measurements using significant unobservable inputs	Fair Value Measurements Using Significant Unobservable Inputs (Level 3) (in thousands) Warrant Liability Balance at January 1, 2015 $ 225 Total change in the liability included in earnings (564 ) Fair value of warrants issued 4,247 Fair value of warrants exercised (123 ) Balance at December 31, 2015 3,785 Total change in the liability included in earnings (12,780 ) Fair value of warrants issued 28,472 Fair value of warrants exercised (726 ) Balance at December 31, 2016 $ 18,751

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Schedule of future minimum lease payments, net of receipts due under terms of subleases under all operating leases	Future minimum lease payments, net of receipts due under the terms of subleases, under all operating leases at December 31, 2016 are as follows: (in thousands) Future Payment 2017 $ 952 2018 946 2019 529 2020 428 2021 254 2022 — $ 3,109

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Income Before Income Taxes	Income before income taxes consists of: Year Ended December 31, (in thousands) 2016 2015 Domestic $ (13,930 ) $ (11,276 ) Foreign (4,040 ) (3,428 ) Income before taxes $ (17,970 ) $ (14,704 )
Income tax reconciliation	The provision for income taxes differs from the amount computed by applying the statutory rate as follows: Year Ended December 31, (in thousands) 2016 2015 Income taxes using U.S federal statutory rate $ (6,110 ) $ (4,999 ) Loss of tax benefit of net operating loss carryforwards 68,795 — Loss of tax benefit of state net operating loss carryforwards 13,891 — Loss of tax benefit of tax credit carryforwards 4,023 — Amortization of gain on IP migration 767 767 State income taxes, net of federal benefit (2,576 ) 380 Foreign rate differential 1,141 920 Valuation allowance (75,407 ) 2,649 Derivative charge (4,345 ) (192 ) Stock option exercises and cancellations 53 674 Research and development costs (250 ) (199 ) Other 18 — $ — $ —
Significant components of deferred tax assets	Significant components of the Company’s deferred tax assets are as follows: (in thousands) December 31, 2016 December 31, 2015 Deferred tax assets: Employee compensation accruals $ 1,386 $ 1,279 Accrued liabilities 343 633 Research tax credits 22 3,796 Other 55 66 Net operating losses 6,194 77,906 Total deferred tax assets $ 8,000 $ 83,680 Deferred tax liabilities: Beneficial conversion feature 906 — Total deferred tax liabilities $ 906 $ — Valuation allowance 7,094 83,680 Net deferred tax assets $ — $ —
Summary of Change in Valuation Allowance	The change in valuation allowance is as follows: (in thousands) December 31, 2016 December 31, 2015 Beginning balance $ 83,680 $ 81,223 Charged to costs and expenses (75,407 ) 2,649 Charged to additional paid-in capital (1,854 ) - Charged to retained earnings 1,010 - Charged to other comprehensive income (335 ) (192 ) Ending balance $ 7,094 $ 83,680

Description of Business - Addit

Description of Business - Additional Information (Details)	12 Months Ended
	Dec. 31, 2016USD ($)Installment	Dec. 31, 2015USD ($)	Jun. 13, 2016USD ($)
Organization Consolidation and Presentation of Financial Statements [Line Items]
Net loss	$ 17,971,000	$ 14,704,000
Net cash used in operating activities	14,213,000	16,420,000
Accumulated deficit	$ 279,188,000	$ 261,217,000
Senior Secured Convertible Notes [Member]
Organization Consolidation and Presentation of Financial Statements [Line Items]
Debt instrument, original issuance date	Jun. 13, 2016
Debt instrument, principal face amount	$ 34,351,000		$ 35,000,000
Debt instrument payable number of equal installments | Installment	14

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Additional Information (Details)	Jul. 21, 2016	Jul. 19, 2016	Jun. 13, 2016USD ($)	Jun. 06, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2016USD ($)Segment	Jun. 30, 2016USD ($)
Summary Of Significant Accounting Policies [Line Items]
Maximum period of investments with original maturities from date of acquisition to be cash equivalents						3 months
Reverse stock split ratio	0.0625
Number of business segments | Segment						1
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives						3 years
Reverse stock split ratio		0.1
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives						7 years
Reverse stock split ratio		0.05
Senior Secured Convertible Notes [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt instrument, principal face amount			$ 35,000,000		$ 34,351,000	$ 34,351,000
Senior Secured Convertible Notes [Member] | Series C Warrants [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt instrument, principal face amount							$ 35,000,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt instrument, principal face amount			35,000,000	$ 35,000,000
Proceeds from issuance of notes available for general corporate purposes			3,000,000	3,000,000	3,000,000
Cash proceeds from notes held			29,200,000		26,200,000	26,200,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | First Release Date on December 29, 2016 [Member]
Summary Of Significant Accounting Policies [Line Items]
Cash proceeds from notes held			3,000,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | Subsequent Release Dates Beginning in February 2017 [Member]
Summary Of Significant Accounting Policies [Line Items]
Cash proceeds from notes held			26,200,000		$ 26,200,000	$ 26,200,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | Series C Warrants [Member]
Summary Of Significant Accounting Policies [Line Items]
Proceeds from issuance of notes			$ 32,200,000	$ 32,200,000

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Summary of Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Calculation of net loss and the number of shares used to compute basic and diluted earnings per share [Abstract]
Net loss – basic and diluted		$ (17,971)	$ (14,704)
Net loss per share – basic and diluted	[1]	$ (10.59)	$ (14.56)
Weighted average shares outstanding – basic and diluted	[1]	1,696,237	1,010,105
[1]	reflects a one-for-sixteen (1:16) reverse stock split effected on July 21, 2016

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Summary of Shares Excluded from the Computation of Diluted EPS (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,276,369	1,211,864
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	41,356	47,221
Unvested Restricted Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	18,993	35,955
Warrants [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,216,020	1,128,688

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 346	$ 360
Work-in-process	214	251
Finished goods	100	146
Total Inventory	$ 660	$ 757

Prepaid Expenses and Other Cu40

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Prepaid Expense And Other Assets Current [Abstract]
Insurance premiums	$ 501	$ 625
Kits for clinical use		162
Other	197	173
Total prepaid expenses and other current assets	$ 698	$ 960

Prepaid Expenses and Other Cu41

Prepaid Expenses and Other Current Assets - Additional Information (Details)	Dec. 31, 2016	Dec. 31, 2015
Prepaid Expense And Other Assets Current [Abstract]
Maximum percentage of prepaid expenses and other current assets (in hundredths)	5.00%	5.00%

Property, Plant, and Equipmen42

Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 4,886	$ 4,638
Accumulated depreciation	(3,803)	(3,506)
Property, plant and equipment, net	1,083	1,132
Buildings and Land [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	556	556
Enterprise Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,532	1,520
Leaseholds [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,504	1,305
Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	940	902
Furniture [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 354	$ 355

Property, Plant, and Equipmen43

Property, Plant, and Equipment - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Depreciation expense	$ 305	$ 617

Current Accrued Expenses - Sche

Current Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Clinical trial expenses	$ 1,365	$ 692
Compensation, excluding taxes	933	391
Professional fees	286	220
Short-term portion of lease restructuring	216	219
Other	607	721
Total accrued expenses	$ 3,407	$ 2,243

Current Accrued Expenses - Addi

Current Accrued Expenses - Additional Information (Details)	Dec. 31, 2016	Dec. 31, 2015
Payables And Accruals [Abstract]
Maximum percentage of current liabilities accrued (in hundredths)	5.00%	5.00%

Restructuring Expenses - Additi

Restructuring Expenses - Additional Information (Details) $ in Thousands	Aug. 18, 2014USD ($)	May 22, 2014USD ($)	Dec. 31, 2016USD ($)Lease	Dec. 31, 2015USD ($)
Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Number of sub leases | Lease			2
Restructuring reserve balance			$ 820	$ 1,039
Sub-lease 1 [Member] | Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges		$ 900
Sub Lease 2 [Member] | Facility Closing [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve charges	$ 700
Other non-current liabilities [Member] | Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			600
Accrued Expenses [Member] | Property Subject to Operating Lease [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance			$ 200

Restructuring Expenses - Schedu

Restructuring Expenses - Schedule of Restructuring and Related Costs (Details) - Lease Liability [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Restructuring Cost And Reserve [Line Items]
Restructuring reserve balance	$ 1,039
Payments/Utilizations	(219)
Restructuring reserve balance	$ 820

Convertible Notes Payable - Add

Convertible Notes Payable - Additional Information (Details) $ / shares in Units, shares in Millions	Jun. 13, 2016USD ($)	Jun. 06, 2016USD ($)Installment$ / sharesshares	Dec. 31, 2016USD ($)$ / shares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)	Dec. 31, 2017	Jun. 30, 2016USD ($)
Debt Instrument [Line Items]
Conversion of convertible notes				$ 649,000	$ 0
Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount	$ 35,000,000		$ 34,351,000	34,351,000
Debt discount on senior notes			21,008,000	$ 21,008,000
Debt instrument, original issuance date				Jun. 13, 2016
Debt issuance costs			1,000,000	$ 1,000,000
Amortization of debt issuance costs				$ 300,000
Stock issued to holders as payment on convertible notes payable | shares				1.8
Conversion of convertible notes				$ 600,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount	35,000,000	$ 35,000,000
Debt discount on senior notes		2,800,000	$ 35,000,000	$ 35,000,000
Interest rate upon default			0.00%	0.00%
Rate of interest in event of default				15.00%
Debt instrument interest rate computation terms				The Notes do not bear any ordinary interest. However, interest shall commence accruing immediately upon the occurrence of, and shall continue accruing during the continuance of, an Event of Default (as defined in the SPA), at 15% per annum and shall be computed on the basis of a 360-day year of twelve 30-day months and shall be payable
Proceeds from issuance of notes available for general corporate purposes	3,000,000	$ 3,000,000	$ 3,000,000
Net cash proceeds from notes held in master restricted account as security	$ 29,200,000		26,200,000	$ 26,200,000
Maturity date of notes		Dec. 29, 2017
Amortization payments number of equal installments | Installment		14
Period after original date of issuance of notes for which amortization payment begins	7 months
Debt instrument, original issuance date				Jun. 13, 2016
Debt instrument, conversion price | $ / shares		$ 4.39
Debt discount amortization				$ 14,000,000
Beneficial conversion feature				4,400,000
Debt instrument, put options issued on default and change in control, value			0	0
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | Unrestricted During 2017 [Member]
Debt Instrument [Line Items]
Net cash proceeds from notes held in master restricted account as security	$ 26,200,000		$ 26,200,000	26,200,000
Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member] | Restricted Cash [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes and warrants				$ 26,200,000
Series C Warrants [Member]
Debt Instrument [Line Items]
Warrants exercise price per share | $ / shares			$ 4.83	$ 4.83
Series C Warrants [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Additional issuance of common stock purchase price per share. | $ / shares		0.01
Shares issuable upon warrants exercised description				On December 31, 2017, the number of Warrant Shares issuable upon exercise of the Series C Warrants will be increased by such number of Warrant Shares equal to 75% of the difference of (i) the quotient of (A) the product of (x) the exercise price as of the date of issuance (as adjusted for certain events) multiplied by (y) the number of Warrant Shares as of the date of issuance (as adjusted for certain events), divided by (B) the volume-weighted average price of the Common Stock on the maturity date, less (ii) the number of Warrant Shares as of the date of issuance (as adjusted for certain events).
Warrants exercise price per share | $ / shares		$ 4.83
Warrant exercisable term description				Each Series C Warrant will be exercisable by the holder beginning June 13, 2017 and continuing for a period of five years thereafter.
Warrant exercisable date		Jun. 13, 2017
Warrant exercisable period after vesting		5 years
Series C Warrants [Member] | Securities Purchase Agreement [Member] | Scenario, Forecast [Member]
Debt Instrument [Line Items]
Conditional percentage of increase in number of shares issuable upon exercise of warrants						75.00%
Series C Warrants [Member] | Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount							$ 35,000,000
Series C Warrants [Member] | Senior Secured Convertible Notes [Member] | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes and warrants	$ 32,200,000	$ 32,200,000
Debt discount on senior notes		$ 27,800,000
Shares issuable upon warrants exercised | shares		6.8

Convertible Notes Payable - Sum

Convertible Notes Payable - Summary of Convertible Notes Outstanding (Details) - Senior Secured Convertible Notes [Member] - USD ($)	Dec. 31, 2016	Jun. 13, 2016
Debt Instrument [Line Items]
Convertible notes payable, principal	$ 34,351,000	$ 35,000,000
Debt discounts	(21,008,000)
Net convertible note payable	$ 13,343,000

Stockholders' Equity - Reverse

Stockholders' Equity - Reverse Stock Split - Additional Information (Details)	Jul. 21, 2016$ / sharesshares	Jul. 19, 2016shares	Dec. 31, 2016$ / sharesshares	Jul. 18, 2016shares	Dec. 31, 2015$ / sharesshares
Stockholders Equity Note [Line Items]
Reverse stock split ratio	0.0625
Number of fractional shares were issued in connection with the reverse stock split	0
Common stock, par value (in dollars per share) | $ / shares	$ 0.01		$ 0.01		$ 0.01
Common stock, shares authorized (in shares)		500,000,000	500,000,000	170,000,000	500,000,000
Minimum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio		0.1
Maximum [Member]
Stockholders Equity Note [Line Items]
Reverse stock split ratio		0.05

Stockholders' Equity - Stock an

Stockholders' Equity - Stock and Warrant Issuances - Additional Information (Details) - USD ($)	1 Months Ended				12 Months Ended
	Oct. 31, 2016	Jul. 31, 2015	Feb. 28, 2015	Oct. 31, 2013	Dec. 31, 2016	Jun. 30, 2016	Jun. 13, 2016	Dec. 31, 2015	Oct. 20, 2015	Dec. 31, 2014
Stockholders Equity Note [Line Items]
Sale of common stock, net of expenses (in shares)	425,000	600,000	153,750	81,875
Proceeds from issuance of private placement	$ 1,200,000		$ 2,600,000	$ 7,500,000
Net proceeds from issuance of private placement	$ 1,100,000		$ 2,500,000	$ 6,900,000
Number of warrants outstanding (in shares)					7,216,020			1,128,688		53,134
Sale of units to underwriter		600,000
Proceeds of common stock issued, net of related expenses		$ 6,000,000
Maximum [Member]
Stockholders Equity Note [Line Items]
Warrants exercisable per share price (in dollars per share)					$ 112.64			$ 112.64		$ 112.64
Maximum offering and selling of stock and securities that entity make to raise capital									$ 77,400,000
Entity public float pursuant to SEC regulations									$ 75,000,000
Senior Secured Convertible Notes [Member]
Stockholders Equity Note [Line Items]
Debt instrument, principal face amount					$ 34,351,000		$ 35,000,000
Series A Common Stock Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants exercisable per share price (in dollars per share)					$ 1.61
Number of warrants outstanding (in shares)					300,000
Warrants exercised (in shares)					300,000
Net proceeds from exercise of warrants					$ 400,000
Number of warrants converted		400,000						100,000
Gross proceeds from underwriting offering		$ 7,000,000
Warrants expiry period					5 years
Series B Common Stock Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants exercised (in shares)					100,000
Net proceeds from exercise of warrants					$ 800,000
Number of warrants converted		600,000
Remaining outstanding warrants expired					400,000
Warrants expiration date					Jan. 29, 2016
Series A and B Common Stock Warrants [Member]
Stockholders Equity Note [Line Items]
Value of warrants issued		$ 3,400,000
2013 Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants issued (in shares)				37,000
Value of warrants issued				$ 1,900,000
Warrants exercisable per share price (in dollars per share)					$ 112.64
Number of warrants outstanding (in shares)					36,848
Term period for warrants					5 years
February 2015 Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants issued (in shares)			69,000
Value of warrants issued			$ 800,000
Warrants exercisable per share price (in dollars per share)					$ 1.61
Number of warrants outstanding (in shares)					30,238
Term period for warrants					5 years
Warrants exercised (in shares)					40,000
Net proceeds from exercise of warrants					$ 100,000
Series C Warrants [Member]
Stockholders Equity Note [Line Items]
Value of warrants issued						$ 27,800,000
Warrants exercisable per share price (in dollars per share)					$ 4.83
Number of warrants outstanding (in shares)					6,800,000
Percentage of increased number of warrant shares issuable upon exercise					75.00%
Description of warrant issued upon exercise					On December 31, 2017, the number of Warrant Shares issuable upon exercise of the Series C Warrants will be increased by such number of Warrant Shares equal to 75% of the difference of (i) the quotient of (A) the product of (x) the exercise price as of the date of issuance (as adjusted for certain events) multiplied by (y) the number of Warrant Shares as of the date of issuance (as adjusted for certain events), divided by (B) the volume-weighted average price of the Common Stock on the maturity date, less (ii) the number of Warrant Shares as of the date of issuance (as adjusted for certain events).
Warrants holding period					1 year
Warrants exercisable period					5 years
Series C Warrants [Member] | Senior Secured Convertible Notes [Member]
Stockholders Equity Note [Line Items]
Number of warrants converted						6,800,000
Debt instrument, principal face amount						$ 35,000,000
October 2016 Warrants [Member]
Stockholders Equity Note [Line Items]
Warrants issued (in shares)	148,750
Value of warrants issued	$ 300,000
Warrants exercisable per share price (in dollars per share)					$ 1.61
Number of warrants outstanding (in shares)					78,750
Term period for warrants					5 years
Warrants exercised (in shares)					70,000
Net proceeds from exercise of warrants					$ 100,000

Stockholders' Equity - Stock In

Stockholders' Equity - Stock Incentive Plans - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 31, 2016	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option compensation expense		$ 161,000	$ 349,000
Stock options granted			32,765
Additional compensation expense relating to stock options		55,000
Restricted stock compensation expense		266,000	$ 308,000
Additional compensation expense relating to restricted stock		100,000
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option compensation expense		$ 200,000	300,000
Stock options granted		0
Remaining average recognition period for unrecognized compensation expense		1 year 22 days
Aggregate intrinsic value of options outstanding and exercisable		$ 0
Closing stock price (in dollars per share)		$ 0.92
Stock Options [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted, term		10 years
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Remaining average recognition period for unrecognized compensation expense		1 year 1 month 13 days
Restricted stock compensation expense		$ 300,000	$ 300,000
2004 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for the issuance (in shares)		11,719
2009 Stock Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares reserved for the issuance (in shares)	94,141	200,391
Increased number of shares (in shares)	106,250
Shares available for grant		120,883

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Stock Options, Number of Options [Roll Forward]
Outstanding, beginning of period (in shares)	47,221	17,577
Granted (in shares)		32,765
Forfeited (in shares)	(5,865)	(3,121)
Outstanding, end of period (in shares)	41,356	47,221	17,577
Exercisable (in shares)	26,774
Stock Options, Exercise Price per Share [Roll Forward]
Granted (in dollars per share)		$ 19.04
Stock Options, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 122.40	378.08
Granted (in dollars per share)		19.04
Forfeited (in dollars per share)	23.95	480.16
Outstanding, beginning of period (in dollars per share)	135.77	$ 122.40	$ 378.08
Exercisable (in dollars per share)	$ 199.31
Stock Options, Weighted Average Remaining Life Years [Abstract]
Outstanding	7 years 10 months 24 days	8 years 11 months 12 days	8 years 9 months 29 days
Exercisable	7 years 7 months 17 days
Minimum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 19.04	$ 19.84
Forfeited (in dollars per share)	19.04	19.04
Outstanding, end of period (in dollars per share)	19.84	19.04	$ 19.84
Exercisable (in dollars per share)	19.04
Maximum [Member]
Stock Options, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share)	3,921.92	3,921.92
Forfeited (in dollars per share)	545.28	2,713.60
Outstanding, end of period (in dollars per share)	3,788.80	$ 3,921.92	$ 3,921.92
Exercisable (in dollars per share)	$ 3,788.80

Stockholders' Equity - Assumpti

Stockholders' Equity - Assumptions Used to Determine Estimated Fair Value of Stock Options Granted (Details)	12 Months Ended
	Dec. 31, 2015$ / shares
Assumptions used to determine the fair value of stock options [Abstract]
Weighted average grant date fair value (in dollars per share)	$ 28.48
Stock Options [Member]
Assumptions used to determine the fair value of stock options [Abstract]
Weighted average risk-free interest rates (in hundredths)	1.82%
Weighted average expected volatility (in hundredths)	97.70%
Weighted average expected option term (in years)	5 years 1 month 24 days
Weighted average grant date fair value (in dollars per share)	$ 0.89

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Non-vested Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Non-vested Options, Number of Options [Roll Forward]
Non-vested, beginning of period (in shares)	35,471	14,116
Granted (in shares)		32,765
Vested (in shares)	(15,671)	(9,994)
Forfeited (in shares)	(5,218)	(1,416)
Non-vested, end of period (in shares)	14,582	35,471
Non-vested Options, Weighted Average Exercise Price [Roll Forward]
Non-vested, beginning of period (in dollars per share)	$ 22.55	$ 332.16
Granted (in dollars per share)		28.48
Vested (in dollars per share)	26.85	421.60
Forfeited (in dollars per share)	19.23	574.72
Non-vested, end of period (in dollars per share)	$ 19.11	$ 22.55

Stockholders' Equity - Summar56

Stockholders' Equity - Summary of Restricted Stock Activity (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Restricted Stock, Number of Shares [Roll Forward]
Outstanding, beginning of period (in shares)	35,995	1,857
Granted (in shares)	4,687	36,000
Vested (in shares)	(19,189)	(1,854)
Forfeited (in shares)	(2,500)	(8)
Outstanding, end of period (in shares)	18,993	35,995
Restricted Stock, Weighted Average Grant Date Fair Value [Roll Forward]
Non-vested, beginning of period (in dollars per share)	$ 19.04	$ 269.44
Granted (in dollars per share)	4.32	41.60
Vested (in dollars per share)	15.44	217.60
Forfeited (in dollars per share)	19.04	54.40
Non-vested, end of period (in dollars per share)	$ 19.04	$ 19.04

Stockholders' Equity - Summar57

Stockholders' Equity - Summary of Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Warrants outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	1,128,688	53,134
Issued (in shares)	7,031,929	1,091,844
Exercised (in shares)	(499,633)	(13,457)
Expired (in shares)	(444,964)	(2,833)
Outstanding, end of period (in shares)	7,216,020	1,128,688	53,134
Warrants, Weighted Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 16.02	$ 86.69
Issued (in dollars per share)	4.80	12.80
Exercised (in dollars per share)	2.75	13.12
Expired (in dollars per share)	5.68	13.12
Outstanding, end of period (in dollars per share)	$ 5.20	$ 16.02	$ 86.69
Weighted average remaining life	5 years 7 months 2 days	2 years 1 month 28 days	2 years 9 months 11 days
Minimum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)	$ 1.61	$ 11.84	$ 28
Maximum [Member]
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, (in dollars per share)	$ 112.64	$ 112.64	$ 112.64

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)Input	Dec. 31, 2015USD ($)
Fair Value Disclosures [Abstract]
Number of inputs used for valuation of warrants | Input	6
Derivative warrant liability [Abstract]
Warrant liability fair value adjustment	$ 12,780	$ 564
Derivative warrant liabilities	$ 18,751	$ 3,785

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Warrants (Details)	12 Months Ended
	Dec. 31, 2016
October 2016 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	95.03%
Risk free interest rates (in hundredths)	1.93%
Expected life (in years)	4 years 9 months 18 days
June 2016 Series C Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	94.19%
Risk free interest rates (in hundredths)	2.01%
Expected life (in years)	5 years 6 months
July 2015 Series A Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	95.51%
Risk free interest rates (in hundredths)	1.59%
Expected life (in years)	3 years 7 months 6 days
February 2015 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	95.52%
Risk free interest rates (in hundredths)	1.47%
Expected life (in years)	3 years 1 month 6 days
October 2013 Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected volatility (in hundredths)	152.70%
Risk free interest rates (in hundredths)	1.20%
Expected life (in years)	1 year 9 months 18 days

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Recurring [Member] - Derivative Instruments Liabilities [Member] - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Liabilities [Abstract]
Total Liabilities	$ 18,751	$ 3,785
Level 3 [Member]
Liabilities [Abstract]
Total Liabilities	$ 18,751	$ 3,785

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Roll Forward]
Beginning balance	$ 3,785	$ 225
Total change in the liability included in earnings	(12,780)	(564)
Fair value of warrants issued	28,472	4,247
Fair value of warrants exercised	(726)	(123)
Ending balance	$ 18,751	$ 3,785

Commitments Additional Informat

Commitments Additional Information (Details)	1 Months Ended		12 Months Ended
	Oct. 31, 2016USD ($)ft²	Mar. 31, 2016USD ($)ft²	Dec. 31, 2016USD ($)ft²	Dec. 31, 2016EUR (€)	Dec. 31, 2015USD ($)
Operating Leased Assets [Line Items]
Rent expense			$ 500,000		$ 400,000
Office Space at 810 Seventh Avenue, New York, NY [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) | ft²			8,629
Expansion option, additional square footage of office space (in square feet) | ft²			8,629
Letter of credit [Abstract]
Minimum letter of credit amount required to be maintained under lease agreement			$ 881,297
Expiration date of letter of credit			Feb. 1, 2017	Feb. 1, 2017
Office Space in New York, NY, Lease Amendment [Member]
Operating Leased Assets [Line Items]
Additional square footage of office space leased under exercise of option right (in square feet) | ft²			8,629
Lease expiration date			Mar. 31, 2021	Mar. 31, 2021
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] | Year 4 [Member]
Operating Leased Assets [Line Items]
Annual base rent			$ 996,000
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] | Year 5 [Member]
Operating Leased Assets [Line Items]
Annual base rent			1,000,000
Office Space in New York, NY, Initial Lease and Lease Amendment [Member] | Years Thereafter [Member]
Operating Leased Assets [Line Items]
Annual base rent			$ 1,100,000
Delcath's European Headquarters Lease Agreement [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) | ft²			19,200
Operating lease term			10 years	10 years
Delivery time frame of written notice, minimum			6 months	6 months
Delcath's European Headquarters Lease Agreement [Member] | Year 1 [Member]
Operating Leased Assets [Line Items]
Annual base rent			$ 115,458	€ 106,051
Delcath's European Headquarters Lease Agreement [Member] | Year 2 [Member]
Operating Leased Assets [Line Items]
Annual base rent			146,946	134,974
Delcath's European Headquarters Lease Agreement [Member] | Year 3 [Member]
Operating Leased Assets [Line Items]
Annual base rent			173,187	159,077
Delcath's European Headquarters Lease Agreement [Member] | Year 4 [Member]
Operating Leased Assets [Line Items]
Annual base rent			199,427	183,179
Delcath's European Headquarters Lease Agreement [Member] | Year 5 [Member]
Operating Leased Assets [Line Items]
Annual base rent			199,427	183,179
Delcath's European Headquarters Lease Agreement [Member] | Year 6 Through 10 [Member]
Operating Leased Assets [Line Items]
Annual base rent			197,377	€ 187,209
Office Space At 1633 Broadway, New York, NY [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) | ft²		6,877
Annual base rent		$ 522,652
Letter of credit [Abstract]
Minimum letter of credit amount required to be maintained under lease agreement			$ 130,663
Expiration date of letter of credit			Mar. 1, 2019	Mar. 1, 2019
Park Road Lease Agreement [Member]
Operating Leased Assets [Line Items]
Square footage of office space (in square feet) | ft²	6,000
Annual base rent	$ 48,223
Operating lease term			2 years	2 years
Lease expiration period			2018-10	2018-10

Commitments - Schedule Future M

Commitments - Schedule Future Minimum Lease Payments, Net of Receipts Due Under Terms of Subleases Under All Operating Leases (Details) $ in Thousands	Dec. 31, 2016USD ($)
Future minimum lease payments under all operating leases [Abstract]
2,017	$ 952
2,018	946
2,019	529
2,020	428
2,021	254
Total future minimum payments due	$ 3,109

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating Loss Carryforwards [Line Items]
Income tax provision	$ 0	$ 0
Tax benefit related to the exercise of non qualified stock options	$ 1,000,000
Percentage of valuation allowance against deferred tax assets	100.00%
Valuation allowance increase (decrease)	$ (76,600,000)	2,649,000
Unrecognized tax benefits, interest or penalties accrued	0
ASU 2016-09 [Member]
Operating Loss Carryforwards [Line Items]
Income tax benefit cumulative adjustment to retained earnings	1,000,000
Valuation allowance offset against retained earnings	1,000,000
New York State [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards net, expected to expire unutilized and unavailable to offset future federal taxable income	150,200,000
New York City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards net, expected to expire unutilized and unavailable to offset future federal taxable income	$ 130,500
Tax Year 2013 [Member]
Operating Loss Carryforwards [Line Items]
Open tax period	Dec. 31, 2013
Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open tax period	Dec. 31, 2016
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 209,300,000	184,500,000
Operating loss carryforwards, amount subject to limitations	201,000,000
Operating loss carryforwards, annual limitation	72,500
Operating loss carryforwards net, expected to expire unutilized and unavailable to offset future federal taxable income	205,700,000
Federal [Member] | Expire Between 2018 and 2036 [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	3,600,000
Federal [Member] | Research and Development Tax Credit Carryforwards [Member]
Operating Loss Carryforwards [Line Items]
Tax credit carryforwards	$ 4,000,000	3,800,000
Tax credit carryforwards, expiration dates	2,036
State and City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 2,800,000	2,700,000
Operating loss carryforwards, expiration dates	2,036
Foreign [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 21,100,000	22,100,000
Minimum [Member] | State and City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	27,300,000	27,300,000
Maximum [Member] | State and City [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 153,000,000	$ 109,700,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments [Abstract]
Domestic	$ (13,930)	$ (11,276)
Foreign	(4,040)	(3,428)
Income before taxes	$ (17,970)	$ (14,704)

Income Taxes - Income tax recon

Income Taxes - Income tax reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Provision for income taxes [Abstract]
Income taxes using U.S federal statutory rate	$ (6,110,000)	$ (4,999,000)
Loss of tax benefit of net operating loss carryforwards	68,795,000
Loss of tax benefit of state net operating loss carryforwards	13,891,000
Loss of tax benefit of tax credit carryforwards	4,023,000
Amortization of gain on IP migration	767,000	767,000
State income taxes, net of federal benefit	(2,576,000)	380,000
Foreign rate differential	1,141,000	920,000
Valuation allowance	(75,407,000)	2,649,000
Derivative charge	(4,345,000)	(192,000)
Stock option exercises and cancellations	53,000	674,000
Research and development costs	(250,000)	(199,000)
Other	18,000
Total	$ 0	$ 0

Income Taxes - Significant Comp

Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Employee compensation accruals	$ 1,386	$ 1,279
Accrued liabilities	343	633
Research tax credits	22	3,796
Other	55	66
Net operating losses	6,194	77,906
Total deferred tax assets	8,000	83,680
Deferred tax liabilities:
Beneficial conversion feature	906
Total deferred tax liabilities	906	0
Valuation allowance	7,094	83,680	$ 81,223
Net deferred tax assets	$ 0	$ 0

Income Taxes - Summary of Chang

Income Taxes - Summary of Change in Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Beginning balance	$ 83,680	$ 81,223
Charged to costs and expenses	(75,407)	2,649
Charged to additional paid-in capital	(1,854)
Charged to retained earnings	1,010
Charged to other comprehensive income	(335)	(192)
Ending balance	$ 7,094	$ 83,680

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Subsequent Event [Member] - USD ($) $ / shares in Units, $ in Millions	Feb. 13, 2017	Mar. 28, 2017
Subsequent Event [Line Items]
Closing bid price per NASDAQ listing notification letter	$ 1
Stock market granted additional calendar days	180 days
Stock market granted consecutive trading days preceding the date of notice	30 days
Consecutive business days for closing bid price of common stock	10 days
Master Control Account Agreement [Member]
Subsequent Event [Line Items]
Cash previously funded from holders of notes		$ 6.6
Common Stock Issued [Member]
Subsequent Event [Line Items]
Stock issued to holders as payment on convertible notes payable		109,345,554